- Portugal brings deadly forest fires under control
- Postecoglou defends Solanke after slow start to Spurs career
- US nuclear plant Three Mile Island to reopen to power Microsoft
- Arteta urges Arsenal to take next step in Man City showdown
- Stock markets fall after Fed-fuelled rally
- Top Hezbollah commander 'killed' in Israel strike
- Poland charges Russian over attack on Navalny ally: prosecutors
- Man City have rest 'advantage' in Arsenal showdown: Guardiola
- Maresca has 'no doubt' in Jackson as Chelsea's number nine
- EU chief announces 35 bn euro loan plan for Ukraine before winter
- From TikTok to Hollywood, the irresistible rise of Italy's Khaby Lame
- Verstappen punished for swearing in Singapore press conference
- Sri Lanka lead by 202 in first New Zealand Test
- Brook 'not too fussed' by England's batting in heavy Australia loss
- India's Ashwin 'happy' to embrace pressure
- A modern 'Trojan Horse': two days of mayhem in Lebanon
- Third of Burundi mpox cases in children under five: UN
- Man Utd appoint Foster + Partners to develop Old Trafford 'masterplan'
- Israel-Hezbollah exchanges intensify on Lebanon border
- French mayor sorry for 'no one died' remark over mass rape trial
- Mohamed Al-Fayed, outsider shunned by British high society
- Lawyers say 'monster' late Harrods owner abused dozens of women
- India in box seat after Bumrah takes four against Bangladesh
- Taiwan retains death penalty but limits use to 'exceptional' cases
- Ferrari's Leclerc sets early pace in Singapore ahead of Norris
- 10 years into Huthi rule, some Yemenis count the cost
- France poised to finally get new govt
- Kompany, Alonso call for action on player workload amid strike talks
- Liverpool goalkeeper Alisson doubtful for Bournemouth clash
- Bumrah takes four as India bowl out Bangladesh for 149
- Sri Lanka 134-1 to take upper hand in first New Zealand Test
- Bayern's Kompany calls for game cap for players amid strike talks
- Christie's expands Hong Kong footprint in hope of art market 'pickup'
- Sultry screen legend Sophia Loren turns 90
- Cambodian opposition figure in court on incitement charge
- Bumrah takes three wickets to have Bangladesh in trouble at 112-8
- Kimchi threat as heatwave drives up South Korea cabbage prices
- UK economic data delivers fresh blow to new govt
- China to 'gradually resume' seafood imports from Japan after Fukushima ban
- India minister blames dam release for flooding
- O'Rourke strikes early for Kiwis as Sri Lanka trail by three
- Deep takes two as Bangladesh totter in reply to India's 376
- Israel pounds Lebanon's Hezbollah after device blasts
- Revolution or mirage? Controversy surrounds new Alzheimer's drugs
- Ashwin's 113 powers India to 376 in Bangladesh Test
- Biden opens home to 'Quad' leaders for farewell summit
- Sally Rooney returns with 30-something questions
- Wallabies sense 'massive' chance to upset All Blacks
- Taiwan questions two in probe into Hezbollah pagers
- Viral Korean Olympic shooter scores first acting role as assassin
RBGPF | 5.79% | 60.5 | $ | |
CMSC | -0.12% | 25.09 | $ | |
CMSD | 0.08% | 25.03 | $ | |
SCS | -2.62% | 12.97 | $ | |
RIO | -1.42% | 64.27 | $ | |
RELX | -0.14% | 48.065 | $ | |
BCC | -1.45% | 142.62 | $ | |
NGG | 0.65% | 69.28 | $ | |
JRI | -0.07% | 13.39 | $ | |
GSK | -1.25% | 41.105 | $ | |
BCE | -0.72% | 34.94 | $ | |
AZN | -0.41% | 78.58 | $ | |
RYCEF | 0.14% | 6.96 | $ | |
BTI | -0.22% | 37.489 | $ | |
VOD | -0.45% | 10.015 | $ | |
BP | -0.86% | 32.48 | $ |
US begins clinical trial to test monkeypox vaccine
US health authorities announced Thursday they would carry out a clinical trial to test different dosing strategies of the Jynneos monkeypox vaccine, amid uncertainty over its effectiveness.
The trial will enroll 200 adults aged 18-50 across the country, and is sponsored by the National Institute of Allergy and Infectious Diseases.
The Jynneos vaccine, manufactured by Denmark-based Bavarian Nordic, has been approved by the United States for the prevention of smallpox and monkeypox in people aged 18 and older.
But while the highest-risk group, men who have sex with men, are encouraged to get the vaccine, there is no clear picture of how well it works in real world settings.
The new trial isn't designed to produce an efficacy estimate, but rather measure the immune response of different dosing levels and administration methods.
"NIAID's trial of JYNNEOS will provide important information on the immunogenicity, safety, and tolerability of alternative dosing approaches that would expand the current supply of vaccine," said NIAID director Anthony Fauci in a statement.
Among the participants, one group will be injected subcutaneously -- that is, under the skin. The vaccine is based on attenuated virus that is modified so it can't replicate, and is given in two doses 28 days apart.
A second group will receive their shots intradermally, meaning between the layers of the skin. This strategy is meant to expand the availability of vaccines because it uses one-fifth of the standard dose.
A third group will also receive their shots intradermally, but at half the dosing level of the second group.
Scientists will test the peak immune responses and compare the side effects across the groups.
President Joe Biden's administration has bet heavily on the Jynneos vaccine to stem the spread of monkeypox, which has affected more than 20,000 people in the United States since May.
But the question of how well the shot prevents infection versus minimizing disease would require further study to answer.
The current global outbreak is primarily affecting gay and bisexual men.
Historically, the virus has been spread via direct contact with lesions, body fluids and respiratory droplets, and sometimes through indirect contamination via surfaces such as shared bedding.
But in this outbreak, there is preliminary evidence that sexual transmission may also play a role.
The virus causes painful skin lesions and flu-like symptoms.
Most people fully recover, but the disease can cause serious complications, including bacterial infections, brain inflammation and death.
P.M.Smith--AMWN